01 Advancements in Diagnostic Technologies: Shift from Conventional Serology to Multiplex & Sequencing Platforms A major trend in the global market is the shift from basic antibody or antigen-based serological tests toward more advanced molecular diagnostics, including multiplex PCR, targeted sequencing, and rapid point-of-care assays, enabling faster, more precise, and serotype-specific detection. For example, in December 2024, MGI Tech released its ATOPlex DENV1-4 Targeted Sequencing Package, covering all four dengue virus serotypes. The solution streamlined nucleic acid extraction, library preparation, sequencing, and data analysis, delivering results in about 12 hours for improved surveillance and control. This trend reflected a strong market demand for diagnostics that are faster, more comprehensive, and capable of serotype differentiation.
02 Mandated Outbreak Surveillance Boosts Dengue Testing Uptake A key growth trend for the dengue testing market is the global push for mandatory disease surveillance and lab confirmation protocols. Health authorities required faster and more accurate testing, especially in outbreak-prone regions. Recently WHO released updated guidance recommending countries to expand laboratory-based dengue diagnostics, even in remote regions, to improve outbreak response and early case detection. This supported countries in detecting cases earlier, managing outbreaks faster, and preventing hospital overload. It also pushed governments to fund more test kits, upgrade public labs, and adopt point-of-care tools. These actions directly increased the demand for potent dengue testing solutions, accelerating overall market growth and adoption globally.
01 Government Initiatives and Public Health Campaigns A key driver in the dengue testing market has been the strong focus of governments and public health agencies on launching initiatives and awareness campaigns that improved diagnostic access, strengthened surveillance systems, and educated communities on dengue prevention. For example, in October 2024, the World Health Organization (WHO) launched its Global Strategic Preparedness, Readiness and Response Plan (SPRR) for dengue, which focused on enhancing laboratory diagnostics, expanding disease surveillance, improving vector control, and supporting better clinical management in affected regions. These coordinated actions raised testing adoption worldwide and created an opportunity for sustained market growth through long-term integration of diagnostics into public health systems.
01 High Cost of PCR-Based Dengue Testing A major restraint in the market is the high cost associated with the advanced laboratory equipment and reagents. For example, in August 2025, as per the article published in BioMed Central Ltd, a study from Dhaka, Bangladesh, evaluating the OnSite Dengue Ag Rapid Test, pointed out that PCR based testing, which is considered the gold standard for detecting dengue, is much more expensive and demands specialized equipment and trained staff, making it less accessible in various healthcare settings.
01 Expansion of Diagnostic Infrastructure in Endemic Regions An opportunity in the global market is the rapid expansion of diagnostic infrastructure in endemic regions to improve disease detection, surveillance, and patient management. For example, in September 2025, India’s Union Health Ministry announced that 869 Sentinel Surveillance Hospitals and 27 Apex Referral Laboratories for provide free dengue testing, with over 5,520 diagnostic kits distributed to states.This reflected an opportunity for diagnostic companies to collaborate with governments and global health agencies, expand supply chains, and develop high-quality dengue testing solutions tailored for large-scale use in endemic areas.
March 2026 Abbott expanded its infectious disease diagnostics portfolio with advanced dengue testing solutions designed to improve early detection, accuracy, and accessibility of disease diagnosis.
September 2025 F. Hoffmann-La Roche introduced enhanced molecular diagnostic technologies supporting faster and more reliable detection of infectious diseases, including dengue.
May 2025 Bio-Rad Laboratories expanded its diagnostic testing portfolio with improved immunoassay and molecular testing solutions for infectious disease detection.